Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation
Pfizer vs. J&J: Comparing Growth, Patent Risks and Valuation The Globe and Mail
Covered in this story
Analyst targets on Pfizer
- HSBC: $23.7 → $28 by Jul 2027 · Hold via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $PFE yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Pfizer →Dalsna Finance is currently tracking 49 stories mentioning Pfizer, the earliest published 22 May 2026.
Summary aggregated from The Globe and Mail's public RSS feed. The full reporting belongs to The Globe and Mail — please read it on their site.